常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.66/2.08
|
|
企业价值
1.92B
|
| 资产负债 |
|
每股账面净值
13.51
|
| 现金流量 |
|
现金流量率
0.10
|
| 损益表 |
|
收益
358.71M
|
|
每股收益
3.88
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/16 11:09 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. |

22.25 
